Publication

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.

Authors not recorded

Oncotarget2016PMID 26689995PMC4823091stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (5)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 5

cancerLung Non-Small Cell Carcinomacivic_curation1.00
drugAfatinibcivic_curation1.00
drugPertuzumabcivic_curation1.00
geneERBB3civic_curation1.00
variantERBB3 V855Acivic_curation1.00

Curated evidence

Evidence citing this paper (2)

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB3 V855A2
Afatinib + PertuzumabSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID1845 Case report on a novel V855A mutation located in exon 21 of the HER3 tyrosine kinase domain and found in the tumor specimen of an adolescent patient with a chemotherapy-resistant advanced NSCLC. Prote… (full text at CIViC) PMID 26689995 · Umelo et al., 2016 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	submitted	EID10060 BaF3 cells were trasnfected with WT HER2, WT HER3, or mutant HER3 (V855A). The HER3 mutant enhanced phosphorylation only in the presence of HER2 WT. PMID 26689995 · Umelo et al., 2016 · Open in CIViC	civic